These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 3829001)
1. Development and characterization of a human colon adenocarcinoma xenograft deficient in thymidine salvage. Houghton PJ; Houghton JA; Germain G; Torrance PM Cancer Res; 1987 Apr; 47(8):2117-22. PubMed ID: 3829001 [TBL] [Abstract][Full Text] [Related]
2. Mutation(s) of the thymidylate synthase gene of human adenocarcinoma cells causes a thymidylate synthase-negative phenotype that can be attenuated by exogenous folates. Houghton PJ; Rahman A; Will CL; Dolnick BJ; Houghton JA Cancer Res; 1992 Feb; 52(3):558-65. PubMed ID: 1732043 [TBL] [Abstract][Full Text] [Related]
3. N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)urea, a novel agent equally cytotoxic to nonproliferating human colon adenocarcinoma cells. Houghton PJ; Bailey FC; Germain GS; Grindey GB; Witt BC; Houghton JA Cancer Res; 1990 Jan; 50(2):318-22. PubMed ID: 2295071 [TBL] [Abstract][Full Text] [Related]
4. Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Houghton JA; Maroda SJ; Phillips JO; Houghton PJ Cancer Res; 1981 Jan; 41(1):144-9. PubMed ID: 7448754 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. Houghton JA; Cheshire PJ; Hallman JD; Lutz L; Luo X; Li Y; Houghton PJ Clin Cancer Res; 1996 Jan; 2(1):107-18. PubMed ID: 9816097 [TBL] [Abstract][Full Text] [Related]
6. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Schultz RM; Patel VF; Worzalla JF; Shih C Anticancer Res; 1999; 19(1A):437-43. PubMed ID: 10226579 [TBL] [Abstract][Full Text] [Related]
7. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. van der Wilt CL; Backus HH; Smid K; Comijn L; Veerman G; Wouters D; Voorn DA; Priest DG; Bunni MA; Mitchell F; Jackman AL; Jansen G; Peters GJ Cancer Res; 2001 May; 61(9):3675-81. PubMed ID: 11325838 [TBL] [Abstract][Full Text] [Related]
8. Biochemical mechanisms in colon xenografts: thymidylate synthase as a target for therapy. Houghton PJ; Houghton JA; Hazelton BJ; Radparvar S Invest New Drugs; 1989 Apr; 7(1):59-69. PubMed ID: 2661484 [TBL] [Abstract][Full Text] [Related]
9. Activity of thymidine as a chemotherapeutic agent against human tumor xenografts in nude mice. Howell SB; Jenkins RS; Streifel J Cancer Res; 1979 Oct; 39(10):3875-80. PubMed ID: 476623 [TBL] [Abstract][Full Text] [Related]
10. Mutants of human colon adenocarcinoma, selected for thymidylate synthase deficiency. Houghton PJ; Germain GS; Hazelton BJ; Pennington JW; Houghton JA Proc Natl Acad Sci U S A; 1989 Feb; 86(4):1377-81. PubMed ID: 2537495 [TBL] [Abstract][Full Text] [Related]
11. Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model. Emura T; Nakagawa F; Fujioka A; Ohshimo H; Kitazato K Oncol Rep; 2004 Feb; 11(2):381-7. PubMed ID: 14719072 [TBL] [Abstract][Full Text] [Related]
12. Biological properties of the human colonic adenocarcinoma cell line SW 620 grown as a xenograft in the athymic mouse. Stragand JJ; Barlogie B; White RA; Drewinko B Cancer Res; 1981 Sep; 41(9 Pt 1):3364-9. PubMed ID: 7260902 [TBL] [Abstract][Full Text] [Related]
13. Adriamycin response of two human tumor xenografts using a double-radiolabel organ culture method. Sullivan JL; Sullivan LG Neoplasma; 1989; 36(6):685-90. PubMed ID: 2615871 [TBL] [Abstract][Full Text] [Related]
14. Cellular pharmacology of 5-fluorouracil in a human colon adenocarcinoma cell line selected for thymidine kinase deficiency. Radparvar S; Houghton PJ; Germain G; Pennington J; Rahman A; Houghton JA Biochem Pharmacol; 1990 Jun; 39(11):1759-65. PubMed ID: 2344373 [TBL] [Abstract][Full Text] [Related]
15. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858 [TBL] [Abstract][Full Text] [Related]
16. The mismatch repair protein, hMLH1, mediates 5-substituted halogenated thymidine analogue cytotoxicity, DNA incorporation, and radiosensitization in human colon cancer cells. Berry SE; Garces C; Hwang HS; Kunugi K; Meyers M; Davis TW; Boothman DA; Kinsella TJ Cancer Res; 1999 Apr; 59(8):1840-5. PubMed ID: 10213489 [TBL] [Abstract][Full Text] [Related]
17. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine. Berry SE; Davis TW; Schupp JE; Hwang HS; de Wind N; Kinsella TJ Cancer Res; 2000 Oct; 60(20):5773-80. PubMed ID: 11059773 [TBL] [Abstract][Full Text] [Related]
18. Thymidylate synthetase-deficient mouse FM3A mammary carcinoma cell line as a tool for studying the thymidine salvage pathway and the incorporation of thymidine analogues into host cell DNA. Balzarini J; De Clercq E; Ayusawa D; Seno T Biochem J; 1984 Jan; 217(1):245-52. PubMed ID: 6696722 [TBL] [Abstract][Full Text] [Related]
19. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Dangles-Marie V; Pocard M; Richon S; Weiswald LB; Assayag F; Saulnier P; Judde JG; Janneau JL; Auger N; Validire P; Dutrillaux B; Praz F; Bellet D; Poupon MF Cancer Res; 2007 Jan; 67(1):398-407. PubMed ID: 17210723 [TBL] [Abstract][Full Text] [Related]
20. Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion. Bernacki RJ; Oberman EJ; Seweryniak KE; Atwood A; Bergeron RJ; Porter CW Clin Cancer Res; 1995 Aug; 1(8):847-57. PubMed ID: 9816054 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]